Table 3.
HIV-positive patients with cervical cancer: main characteristics of the studies included in the review
| Study, reference | Sample size | Study period | Country | Study type | Characteristics of cervical cancer | Median age (years) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage (%) | Histology (%) | |||||||||||||
| I | IIA | IIB | IIIA | IIIB | IVA | Squamous | Adeno | Others | ||||||
| Gichangi 43 | 36 | 1989–1998 | Kenya | Retro | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Moodley 44 | 45 | 2003 | South Africa | Retro | I-IIA (14%) | IIB/IIIA (27%) | IIIB/IVA (49%) | 89 | 4 | 7 | 41 | |||
| Shrivastava 45 | 42 | 1997–2003 | India | Retro | 5 | 7 | 29 | – | 45 | 5 | 98 | 2 | – | 41 |
| Gichangi 15 | 41 | 2000–2002 | Kenya | Prosp (NR) | 2.4 | – | 63.4 | – | 31.7 | 2.4 | 87 | 5.3 | 7.7 | 38.1 |
| Msadabwe 26 | 25 | 2009 | South Africa | Prosp (RCT) | NA | NA | NA | NA | NA | NA | NA | NA | NS | 39.5 |
| Simonds et al. 29 | 59 | 2007–2010 | South Africa | Retro | I/II (16.9%) | III/IV (83.1%) | 94.9 | 1.7 | 3.4 | 41 | ||||
| Munkukpa 23 | 55 | 2012 | Zambia | Prosp (NR) | 13 | 7 | 60 | 2 | 18 | – | 98.2 | 1.8 | – | 40 |
| Al-Noseery 27 | 137 | 2012 | Zambia | Retro | NA | NA | NA | NA | NA | NA | NA | NA | NS | 42 |
Sq, squamous cell carcinoma; Adeno, adenocarcinoma; Retro, retrospective cohort study; Prosp, prospective; NR, nonrandomized; RCT, randomized controlled trial; NA, not available.